TrialClinical and experimental dermatology2021

A phase I, randomized, double-blind study to assess the safety, tolerability and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.

G Berstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.